Evidence map›Paper›PMID 39954062›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Comparison of

Huanhuan Liu, Xiaojun Zhang, Jingfeng Zhang, Yue Pan, Hui Wen, Xiaodan Xu, Shina Wu, Yuan Wang, Cong Zhang, Guangyu Ma and 3 more

Abstract readComparative Study
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Huanhuan Liu *Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Xiaojun Zhang *Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Jingfeng Zhang *Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Yue PanDepartment of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Hui WenDepartment of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Xiaodan XuDepartment of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Shina WuDepartment of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Yuan WangDepartment of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Cong ZhangDepartment of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Guangyu MaDepartment of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Yachao LiuDepartment of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China. yachao301@163.com.
Ruimin WangDepartment of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China. wrm@yeah.com.
Jinming ZhangDepartment of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China. zhangjm301@163.com.ORCID 0000-0002-9425-5180

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aims to investigate the efficacy and safety of prostate-specific membrane antigen (PSMA) radiolabeled with copper-64 (

methods

resultsThe radiochemical purities of

conclusionsBoth NOTA and DOTA are suitable chelators for the development of

trial registrationChinese Clinical Trial Registry ChiCTR2300072655, Registered 20 June 2023.

Indexed as

Chelating AgentsCopper RadioisotopesGlutamate Carboxypeptidase IIHeterocyclic CompoundsHeterocyclic Compounds, 1-RingPositron Emission Tomography Computed TomographyProstatic NeoplasmsAnimalsCell Line, TumorHumansMaleMiceRadiopharmaceuticalsTissue Distribution1,4,7-triazacyclononane-N,N',N''-triacetic acidChelating AgentsCopper-64Copper RadioisotopesGlutamate Carboxypeptidase IIHeterocyclic CompoundsHeterocyclic Compounds, 1-RingRadiopharmaceuticals64Cu-DOTA-PSMA-364Cu-NOTA-PSMA-3QBifunctional chelating agentProstate cancerQPSMA-PET/CT

Identifiers

PMID39954062
PMCPMC12162759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.